• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Centers for Medicare & Medicaid Services

Geneoscopy’s ColoSense Medicare win puts stool RNA testing into the colorectal screening mainstream

By Pallavi Madhiraju on June 9, 2026   Medical Devices & Diagnostics  

Geneoscopy’s ColoSense Medicare win puts stool RNA testing into the colorectal screening mainstream

Medicare coverage gives ColoSense a bigger test: can stool RNA screening move from FDA approval to real colorectal cancer adoption?

Imbed Biosciences wins CMS HCPCS code for Microlyte PainGuard, but will billing clarity translate into wound care adoption?

By Pallavi Madhiraju on April 7, 2026   Medical Devices & Diagnostics  

Imbed Biosciences wins CMS HCPCS code for Microlyte PainGuard, but will billing clarity translate into wound care adoption?

Imbed Biosciences secured CMS HCPCS code A2040 for Microlyte PainGuard. Read what it changes for wound care adoption, billing, and reimbursement.

Recent Posts

  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
  • Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes